Skip to main content
Clinical Trials/NL-OMON52864
NL-OMON52864
Recruiting
Phase 3

asal High-Flow Therapy to treat COPD exacerbations: a matter of monitoring and controlling settings? - High-TeC

niversitair Medisch Centrum Groningen0 sites158 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
158
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • History of COPD Global Initiative of Obstructive Lung Diseases (GOLD) stage
  • II to IV (FEV1\< 80% of predicted with an FEV1/forced vital capacity (FVC) ratio
  • \<70\), with a history of at least 10 pack years smoking.
  • At least 1 COPD exacerbation in the year prior to the index hospital
  • admission (exacerbation defined as worsening of pulmonary symptoms requiring
  • oral steroids and/or antibiotics and/or hospital admission)
  • Being admitted to the hospital with a COPD exacerbation
  • Written informed consent is obtained

Exclusion Criteria

  • No lung function data available, • The presence of another acute condition
  • (e.g. pneumonia, acute congestive heart failure, pulmonary embolus) explaining
  • or significantly contributing to the index admission, • Inability to comply
  • with the tests, • The presence of another chronic lung disease (e.g. asthma,
  • restrictive lung disease).
  • Already on non\-invasive ventilation or nasal high flow therapy (at home
  • or during the exacerbation)

Outcomes

Primary Outcomes

Not specified

Similar Trials